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Objective. Our aim was to investigate the eﬀects of IL-6 blockade on the progression of Mycobacterium tuberculosis (TB) and
compare them with those of TNF-α blockade in mice. Methods. Mice were intravenously infected with TB and injected with
antibodies.Survivalwasmonitoredandhistologicalandimmunologicalstudieswerecarriedout.Results.Allanti-IL-6RAb-treated
mice and 8 of 10 control mice survived until sacriﬁced 224 days after TB challenge, whereas anti-TNF-α Ab-treated mice all died
between 120 and 181 days. Anti-IL-6R Ab-treated mice exhibited no signiﬁcant diﬀerences in TB CFU in organs, including the
lungs, and no deterioration in histopathology compared to control mice at 4 weeks. In contrast, anti-TNF-α Ab-treated mice
exhibited increased TB CFU and greater progression of histopathological ﬁndings in organs than control mice. Spleen cells from
anti-TNF-α Ab-treated mice had decreased antigen-speciﬁc response in IFN-γ release and proliferation assays.The results in anti-
IL-6R Ab-treated mice suggest that spleen cell responses were decreased to a lesser degree. Similar results were obtained in IL-6
knockout (KO) mice, compared with TNF receptor 1 (TNFR1) KO and TNFR1/IL-6 double KO (DKO) mice. Conclusion.I L - 6 R
blockade promotes the progression of TB infection in mice far less than TNF-α blockade.
1.Introduction
Unregulated cell-mediated immunity may lead to chronic
autoimmune inﬂammatory diseases such as rheumatoid
arthritis (RA). Proinﬂammatory cytokines such as TNF-α
and IL-6 play important roles in the development and
progression of these diseases. As a result, TNF-α blockers,
such as inﬂiximab and etanercept, and the anti-IL-6 receptor
(IL-6R) antibody (Ab) tocilizumab(TCZ) have exhibited
eﬃcacy superior to conventional DMARDs in the treatment
of RA [1–6]. One concern with anti-TNF-α Ab therapy,
however, is that TNF-α is essential for protection against
Mycobacterium tuberculosis (TB), and it has, in fact, been
reported that anti-TNF-α Ab therapy is associated with
reactivation of tuberculosis [7–11]. As is well known,
TB grows inside macrophages and is killed by activated
macrophages. Granuloma formation is critical in preventing
TB infection in which TNF plays central roles [11]. It is,
therefore, thought that inhibition of granuloma formation
is the major mechanism of reactivation of TB in patients
treated with TNF blockers.
In contrast, no published study has indicated that
IL-6 plays roles in granuloma formation. Accordingly, it is
expected that patients treated with TCZ will not undergo
reactivationofTB.Infact,onestudyfoundthattheincidence
ofTBreactivationinTCZ-treatedpatientsdidnotdiﬀerfrom
that in controls [12]. However, T cell-mediated immunity
also plays a major role in protecting infected hosts from TB.
Th1 cells are induced by IL-12 to secrete IFN-γ,w h i c hw o r k s
with IL-2 and IL-6to inducecytotoxicT cells, which produce
granulysin, leading tothedeathofTBinsideofmacrophages.
Thus, IL-6 is of critical importance for acquired immunity
to TB [13]. In fact, it has been reported that IL-6 blockade
increased susceptibilityto tuberculosisinIL-6-deﬁcient mice2 Clinical and Developmental Immunology
[14] and anti-IL-6 antibody-treated mice [15]. However,
no reports describing the eﬀects of anti-IL-6R Ab on the
immune mechanisms involved in protection against TB
infection have been published.
Clinically, it is particularly important to determine to
what extent IL-6 blockade by anti-IL-6R antibody promotes
TB infection.
This paper describes experiments conducted to investi-
gate and compare the eﬀects of IL-6 and TNF-α blockade
on the development of TB infection in mice by examining
various indicators of disease in TB-challenged mice treated
with antibodies to IL-6R and TNF-α and also in TB-
challenged IL-6 knockout (KO), TNF-α receptor 1 (TNFR1)
KO, and TNFR1/IL-6 double-KO (DKO) mice.
2.Materialsand Methods
2.1. Animals. Female BALB/c and DBA/1 mice were pur-
chased from Clea Japan (Tokyo, Japan) and Japan SLC
(Shizuoka, Japan), respectively. IL-6 KO, TNFR1 KO, and
TNFR1/IL-6DKOmice(backcrossedwithDBA/1mice)were
kindly provided by Dr. Y. Saeki, Osaka University (Osaka,
Japan) [16].
Themicewereraised underspeciﬁcpathogen-free condi-
tions, maintained in isolator cages, manipulated in laminar
ﬂow hoods, and used between 8 and 10 weeks of age. After
infection with TB, the animals were housed in individual
microisolator cages in a Bio-safety Level (BSL) 3 animal
facility.
2.2. Reagents and Antibodies. Puriﬁed protein derivative of
tuberculin (PPD) was obtained from Japan BCG (Tokyo,
Japan). Killed TB H37Ra (referred to as “killed TB” below)
was obtained from Difco Laboratories (Detroit, MI, USA),
and foetal calf serum was obtained from HyClone (Logan,
UT, USA).
Rat anti-murine IL-6R Ab(clone:MR16-1)wasprepared
by Chugai Pharmaceutical (Tokyo, Japan) [17]. Hamster
monoclonal anti-mouse TNF-α Ab (clone: TN3-19.12),
which has been shown to neutralize murine TNF-α in vivo
[18], was obtained from Techne (Minneapolis, MN, USA).
Puriﬁed rat IgG was obtained from ICN Pharmaceuticals
(Aurora,OH,USA)andusedasthecontrolAbforanti-IL-6R
Ab (referred to below as “control Ab 1”). Hamster IgG was
purchased from Rockland (Gilbertsville, PA, USA) and used
as the control Ab for anti-TNF-α Ab (“control Ab 2”).
2.3. Bacteria. T BH 3 7 R vw a sk i n d l yp r o v i d e db yD r .I .S u g -
awara (JATA, Tokyo, Japan). A single colony was grown by a
method previously reported [19, 20].
2.4. Challenge Infection of Animals and Bacterial Load Deter-
mination. T h em i c ew e r ec h a l l e n g e di . v .w i t h5× 105 colony
formingunits(CFU)ofTB,andtheirsurvivalwasmonitored
daily for 224 days. At 4 and 32 weeks after challenge,
the lungs, spleen, and liver were removed aseptically and
homogenized. Serial dilutions were plated on agar, and the
TB CFU count 14 days later was determined by a method
previously reported [19, 20].
2.5.Administration of Antibodies. BALB/cmicewere injected
with anti-TNF-α Ab or control Ab 2 (300μg/mouse i.p.)
4 days and 1 day before challenge and 4, 9, 14, and 19
days after challenge, or with anti-IL-6R Ab or control Ab 1
4 days before challenge (2000μg i.v.) and then 1 day before
challenge and 4, 9, 14, and 19 days after challenge (500μg
i.p.) (Figure 1). The regimen of administration for anti-
TNF-α Ab and anti-IL-6R Ab was modiﬁed as described in
previously published papers [21, 22].
2.6. Histopathological Analysis. Lung and liver tissues from
t h em i c ew e r eﬁ x e dw i t h1 0 %b u ﬀered formalin and
embedded in paraﬃn. Each block was cut into 4-μm-
thick sections and stained using haematoxylin and eosin.
Semiquantitative morphometric analysis of the patho-
logic slides was performed using a microscope equipped
with a micrometer by our modiﬁcation of the method
of Dascher et al. [23]. In brief, the long and short
axes of each pathologic TB lesion including granuloma
in the ﬁeld (×40 magniﬁcation) were measured, mul-
tiplied, and summed. Three random ﬁelds from each
tissue section were evaluated, and the average score of
the ﬁelds was designated the pathologic TB lesion index
(×10
−2 mm2).
2.7. Proliferative Response of Spleen Cells. To examine T cell
proliferation in response to TB antigen (PPD), spleen cells
(1 × 105) obtained 4 weeks after challenge were cultured
in a 96-well ﬂat bottom plates (Linbro; Flow Laboratories,
McLean, VA, USA) in the presence of PPD (20μg/mL)
for 60h at 37◦C ,a n dt h e np u l s e dw i t h2 0 μLo fB r d U
per well for the ﬁnal 2h of incubation. After removal of
the culture medium, the cells were ﬁxed and the DNA
denatured by adding FixDenat, and cell proliferation was
quantiﬁed based on measurement of BrdU incorporated
during DNA synthesis using a Cell Proliferation ELISA kit
(Roche Diagnostic Corp., Indianapolis, IN, USA) as an
indicator of proliferation.
2.8. Cytokine Production in TB-Speciﬁc Spleen Cells. To
examine TB-speciﬁc T cell immune reactivity, spleen cells
obtained4weeks afterchallengewere culturedintriplicatein
2m Lo fm e d i u m( 2 .5×106 cells/mL) in the presence of PPD
(20μg/mL). Culturesupernatant wascollected48h later,and
the levels of IFN-γ and IL-6 were measured using sandwich
ELISA kits (BD Opt EIA; BD Biosciences Pharmingen)
according to the manufacturer’s instructions [19].
3.Results
3.1. Survival of Ab-Treated Mice after TB Challenge. Of the
5 mice in each control group, 1 mouse in each group died
by 202 days after TB infection (Figure 2). None of the 5
mice in the anti-IL-6R Ab group died by day 224, indicating
that anti-IL-6R Ab treatment did not aﬀect survival. In
contrast, all of the 5 anti-TNF-α Ab-treated mice died
between 120 and 181 days after TB challenge, resulting in
signiﬁcantly shorter survival in the anti-TNF-α Ab-treated
group (P<. 01).Clinical and Developmental Immunology 3
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Figure 1: Protocol of experiment. Mice were treated i.p. or i.v. with antibodies and injected with live TB. Each group consisted of 5 mice.























Figure 2: Survival of TB-challenged BALB/c mice treated with
antibodies to TNF-α and IL-6R. Mice were injected with TB and
antibodies, as shown in Figure 1, and monitored daily for survival.
Each group consisted of 5 mice.
3.2.ConﬁrmationofIL-6Blockade. Sinceithasbeenreported
that anti-IL-6R Ab-treatment signiﬁcantly reduced serum
amyloidA(SAA)production[24],wemeasuredSAA4weeks
after TB infection to conﬁrm blockade of IL-6 signalling by
anti-IL-6R Ab. Production of SAA was almost completely
suppressed in anti-IL-6R Ab-treated mice. In contrast, it
was augmented signiﬁcantly in anti-TNF-α Ab-treated mice
(Table 1).
3.3. TB CFU in Organs from Ab-Treated Mice. There were no
signiﬁcant diﬀerences in TB CFU count in the lungs, spleen,
or liver between anti-IL-6R Ab-treated and control Ab 1-
treated mice 4 weeks after TB challenge. In contrast, anti-
TNF-α Ab-treated mice had signiﬁcantly higher TB CFU
than control Ab 2-treated mice in the lungs (P<. 05), liver
(P<. 01), and spleen (P<. 01) 4 weeks after TB challenge
(Figure 3). CFU count in the lung was higher in control
Table 1: Serum amyloid A levels in BALB/c mice 4 weeks after
challenge with TB.
Treatment Serum amyloid A (μg/mL)∗
M. tuberculosis Antibody n
(−)( −)5 1 5 .1 ±1.8
(+) Control Ab 1 5 29.8 ±1.3
(+) Anti-IL-6R Ab 5 13.4 ±1.3†
(+) Control Ab 2 5 33.6 ±6.9
(+) Anti-TNF-α Ab 5 >189
∗Values are means ± S.E.M.
†Signiﬁcantlydiﬀerent(P<. 01)fromvalueforcontrolAb1(IL-6R)-treated
group on Student’s t-test.
Ab 1 than control Ab 2, though not to a signiﬁcant extent
(Figure 3).
3.4. Histopathological Findings in Ab-Treated Mice. When
lungs and livers obtained from Ab-treated mice 4 weeks after
TB challenge were examined, the lungs from mice treated
with anti-IL-6R Ab (Figure 4(a)-a) and the corresponding
control(Figure 4(a)-b)hadafewTBlesionsincludingpoorly
deﬁned granuloma-like lesions and mononuclear cell inﬁl-
tration.Incontrast,lungsfrommicetreatedwithanti-TNF-α
Ab (Figure 4(a)-c) had more and larger TB lesions including
poorly-deﬁned granuloma-likelesions,with moresigniﬁcant
inﬂammation involving mononuclear cells, neutrophils, and
histiocytes than did mice of the corresponding control
(Figure 4(a)-d).
Anti-TNF-α Ab-treated mice, but not anti-IL-6R Ab-
treated mice, exhibited a signiﬁcant increase in the patho-
logic TB lesion index in lungs (Figure 4(b))a n dl i v e r
(Figure 4(c)) compared with the corresponding controls
(P<. 05).
3.5. Cytokine Production by Spleen Cells from BALB/c Mice


















































Figure 3: Growth of TB in lungs, spleen, and liver of Ab-treated
mice 4 weeks after infection. TB CFU counts in lungs, spleen, and
liver were determined 4 weeks after infection. Results are expressed
as the mean ± S.E.M. of the 5 mice in each group. ∗P<. 05,
∗∗P<. 01 by Student’s t-test. N.S.: Not signiﬁcant by Student’s
t-test.
immune reactivity, spleen cells were cultured in the presence
of PPD for 48h, and T cell activity was assessed by the
amount of IFN-γ in culture supernatant. It is known
that helper T cells are mainly responsible for the ﬁndings
obtained in this assay system [25].
In the presence of PPD, splenic T cells from anti-IL-
6R Ab-treated mice produced less IFN-γ (18% less) and
splenic T cells from anti-TNF-α Ab-treated mice produced
much less IFN-γ (44% less) than the corresponding controls
(Figure 5(a)).
3.6. Proliferation of Spleen Cells from TB-Infected BALB/c
Mice. When spleen cells were cultured in the presence of
PPD to examine T cell proliferation in response to TB anti-
gen, anti-IL-6R Ab did not greatly aﬀect the proliferation of
spleen cells (8% increase), whereas anti-TNF-α Ab treatment
strongly inhibited spleen cell proliferation (52% decrease)
compared with the corresponding control (Figure 5(b)).
3.7. Survival of IL-6 KO and TNFR1 KO DBA/1 Mice after
TB Challenge. The median survival times ofwild-type (WT)
control mice, IL-6 KO mice, and TNFR1 KO mice were 112,
47, and 26 days, respectively (Figure 6(a)). Kaplan-Meyer
analysis demonstrated that both types of KO mice died
earlier than the WT control mice (P<. 01), and that TNFR1
KO mice died even earlier than IL-6 KO mice (P<. 01).
3.8. TB CFU in Organs from IL-6 KO and TNFR1 KO
DBA/1 Mice after TB Challenge. There were no signiﬁcant
diﬀerences between IL-6 KO and WT control mice with
respect to TB CFU counts in the lungs, spleen, or liver 4
weeks after TB challenge. In contrast, 3 of the 5 TNFR1 KO
mice died by the time of assay and both of the remaining
2 mice exhibited increased TB CFU in all 3 types of organs
(Figure 6(b)).
3.9. CytokineProductioninSpleenCells fromKOMice 4 Weeks
after TB Challenge. When stimulated with PPD, spleen cells
from IL-6 KO mice produced less IFN-γ than the WT
control, but TNFR1 KO and DKO mice produced much less
IFN-γ thanIL-6KOmice.Similarly,spleencellsfromTNFR1
KO mice produced somewhat less IL-6 than the WT control,
whereas IL-6 production was almost completely suppressed
in IL-6 KO and DKO mice (Figure 7).
4.Discussion
The experiments described here examined whether IL-6R
blockade inﬂuences the course of TB infection in BALB/c
m i c ea n dc o m p a r e dt h ee ﬀects of IL-6 blockade with those
of TNF-α blockade in the same experiments performed at
the same time. Our ﬁndings clearly demonstrate that anti-
IL-6R Ab treatment increases the susceptibility of these mice
toTBinfectiontosomeextent,butthatthisincreaseisfarless
marked than that induced by anti-TNF-α Ab treatment. This
suggests that the involvement of IL-6 in protection from TB
infection is much less important than that of TNF-α.T ot h e
best ofourknowledge,thisistheﬁrst time suchﬁndings have
been reported, and they have extremely important clinical
implications since they suggest that anti-IL-6R Ab treatment
will not often cause the reactivation of TB in RA patients,
an issue that has limited the clinical use of TNF-α blockers.
In fact, a recently published study found that the incidence
of TB infection in patients treated with TCZ was low [12].
In contrast, many studies have found that patients treated
with TNF blockers suﬀered reactivation of TB [7–11]. These
clinical ﬁndings reﬂect the results obtained here in mice.
After TB challenge, there were no diﬀerences between
anti-IL-6R Ab-treated and control Ab-treated mice with
r e s p e c tt os u r v i v a l( Figure 2) or the proliferation of TB in
the lungs, liver, or spleen 4 weeks after infection (Figure 3).
Furthermore, both groups had a few TB lesions including
poorly deﬁned granuloma-like lesions (arrows) in the lungs
(Figure 4), and there was no signiﬁcant diﬀerence between
them in the proliferation of splenic T cells in response to TB
antigen (Figure 5(b)).
On the other hand, comparison of IFN-γ production
levels showed that there was less PPD-stimulated TB-speciﬁc
splenic helper T cell activity in the anti-IL-6R Ab-treated
mice than in control Ab-treated mice (Figure 5(a)). The
ﬁnding that survival was not aﬀected by anti-IL-6R Ab
treatment shows that the decreases in T cell function and
IFN-γ production were not large enough to aﬀect the
survival ofthe TB-infected mice. It is not surprising that IL-6
blockade only weakly inhibited immune reactivity since, in
addition to IL-6 [26, 27], various other cytokines, such as
IL-2 [28], IL-12 [29], IL-15 [30, 31], IL-17 [32], and IL-23
[33], play important roles in the induction of eﬀector T cells
and in the proliferation and IFN-γ-production of splenic
T cells.
At 32 weeks after infection, compared to control mice,
anti-IL-6R Ab-treated mice had similar TB CFU counts in
the lungs but higher counts in liver and spleen (data not
shown). This is consistent with the ﬁnding of Appelberg
et al. that IL-6 inhibition by anti-IL-6 Ab did not aﬀectClinical and Developmental Immunology 5



















































































Figure 4: Histopathological analysis of mice 4 weeks after TB challenge. (a) Representative photomicrographs of lung tissues sections
harvested from mice administered (a) anti-IL-6R Ab, (b) control Ab 1 (IL-6R), (c) anti-TNF-α Ab, or (d) control Ab 2 (TNF-α). Arrows
indicate TB lesionsincludingpoorly deﬁned granuloma-likelesions(×40,hematoxylin-eosinstain).(b) PathologicTB lesionindex in lungs.
Results are the mean ± S.E.M. of triplicate samples from 5 mice per group. ∗P<. 05 by Student’s t-test. N.S.: Not signiﬁcant by Student’s
t-test.(c)PathologicTB lesionindexinliver.Resultsarethemean±S.E.M.oftriplicate samplesfrom5micepergroup. ∗P<. 05byStudent’s
t-test. N.S.: Not signiﬁcant by Student’s t-test.
the early stages of TB infection, but it did aﬀect the
later stages of it [15]. The increased growth of TB in
anti-IL-6R Ab-treated mice at later stages of infection may
be due to decreased eﬀector T cell activity (Figure 5). As
we and others [26, 27] have reported, IL-6 is an important
cytokine in the induction of eﬀector T cells, which play
important roles in defense mechanisms against TB infection.
In addition, the suppression of IFN-γ production in spleen
cells observed with IL-6 blockade may also contribute to
increased susceptibility to TB infection, since it has been
reported that IL-6 [34]a n dI F N - γ inhibited the growth of
Mycobacterium bovis in macrophages in vitro and that TB-
infected IFN-γ KO mice and IFN-γ Rm u t a n tm i c ew e r e
unable to restrict the growth of TB and developed a fatal
disseminated form of disease [35].
For comparison, we also investigated the eﬀects of TNF-
α blockade. Our ﬁndings conﬁrmed that treatment of mice
with anti-TNF-α antibody enhanced the growth of TB in
the liver, spleen, and lungs, shortening the duration of
survival (Figures 2 and 3), as previously reported [11]. A
number of immature granulomata were observed in the
lungs, spleen, and liver of anti-TNF-α Ab-treated mice
(Figure 4(a)–4(c)). These results are consistent with previ-
ously published ﬁndings [10, 11, 35–39]. Since it has been
reported that stimulation of ﬁbroblast growth by TNF-α is
required for the formation of granulomata that contain TB,
sensitized eﬀector T cells and activated macrophages that
regulate the growth of TB, the aggravation of tuberculosis
in anti-TNF-α Ab-treated mice is thought to be related to
defective granuloma formation or apoptosis and necrosis of
granuloma and lung structure [9–11, 35, 37–39].
We previously reported the eﬃcacy of DNA vaccine
combinations expressing mycobacterial heat shock protein
65 (Hsp65) and IL-12 in protecting against the emergence
of IFN-γ-secreting T cells and activation of proliferative
T cells and cytokine (IFN-γ and IL-2) production upon
stimulation with Hsp65 and antigens from M. tuberculosis
[19]andthatvaccinationwithrecombinantbacteriacarrying
expression plasmids for Ag85A, Ag85B, or MPB/MPT51
was capable of inducing speciﬁc cellular immune responses,
such as proliferative responses of splenocytes and IFN-γ
production by splenocytes [20]. These ﬁndings indicate that
two functions, IFN-γ production and T cell proliferation,
are signiﬁcant in evaluating the eﬀects of antimycobacterial
drugs on immunity against mycobacteria. Anti-TNF-α Ab
more potently inhibited the proliferation of splenic T cells
and the production of IFN-γ in spleen cells than did
anti-IL-6R Ab (Figure 5). These ﬁndings strongly suggest
that TNF-a plays more important roles in mycobacteria
immunity. One possible role of it is inhibition of the
recruitment of immune cells into the spleen, since TNF-α
plays an important role, via induction of chemokines, in6 Clinical and Developmental Immunology
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Figure 5: IFN-γ production and proliferation of spleen cells
obtained 4 weeks after TB infection from Ab-treated mice in
response to TB antigens (PPD). (a) Spleen cells from each group
(n = 5) were pooled and cultured with 20μg of PPD or TB
antigens per mL for 48h, and then IFN-γ in the culture super-
natant was measured. Results are the mean ± S.E.M of triplicate
culture. ∗P<. 01 versus corresponding control by Student’s t-test.
(b) Spleen cells were incubated in the presence of PPD, and BrdU
incorporation in the nucleus was measured as O.D. ∗∗∗(optical
density at 340 nm) as an indicator of proliferation. Results are
the mean ± S.E.M. of triplicate samples from 5 mice per group.
∗P<. 05 and ∗∗P<. 01 versus corresponding control by Student’s
t-test.
recruiting immune cells, including eﬀector T cells [40].
Another is that anti-TNF-α Ab treatment induces a systemic
immunological defect, resulting from exhaustion of the
body due to heavy TB infection. Taken together, these
ﬁndings suggest that the increase in susceptibility to TB
infection in anti-TNF-α Ab-treated mice canbe attributed to






































































Figure 6: Survival and TB CFU in spleen, lungs, and liver of TB-
challenged IL-6 KO, TNFR1 KO, and WT DBA/1 mice. (a) Survival
of TB-infected IL-6 KO mice (n = 5), TNFR1 KO mice (n = 3),and
WT DBA/1 control mice (n = 10). IL-6 KO mice versus TNFR1 KO
mice(P<. 01,Kaplan-Meyeranalysis).(b)TBCFUinlungs,spleen,
and liver 4 weeks after infection in IL-6 KO mice (n = 4), TNFR1
KO mice (n = 2), and WT DBA/1 control mice (n = 10). Results
areexpressed asthemean ± S.E.M.ForTNFR1 KO mice,individual
values are shown.N.S.: Not signiﬁcant by Student’s t-test.
malformation of granulomata and decreased eﬀector T cell
functions.
S i n c eI L - 6K Oa n dT N F R 1K Om i c ec a nb ec o n s i d e r e d
models of IL-6 and TNF-α blockade, we examined TB-
challenged KO mice to supplement our investigation of Ab-
treated mice. Although there were no signiﬁcant diﬀerences
between IL-6 KO and WT mice with respect to TB CFU
counts in liver, lungs, or spleen 4 weeks after TB infection
(Figure 6(b)), the shorter survival time of IL-6 KO mice
(Figure 6(a)) shows that they have increased susceptibility to
TB infection. It should be noted, however, that they survived
longer than TNFR1 KO mice, and that they had higher
TB-antigen-speciﬁc splenic T cell function than TNFR1 KOClinical and Developmental Immunology 7
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TNFR1 and IL-6 DKO
(b)
Figure 7: Cytokine production of PPD-stimulated spleen cells from IL-6 KO, TNFR1 KO, TNFR1 and IL-6 DKO, and WT BALB/C mice.
Singlecell suspensionsobtained from each group 4 weeks after infection in IL-6 KO mice (n = 4), TNFR1 KO mice (n = 2), and WT DBA/1
control mice (n = 10) were pooled and cultured with 20μg/mL of PPD for 48h, and then cytokine concentrations were measured. Results
are means ± S.E.M. of triplicate cultures in each group. ∗P<. 01 by Student’s t-test.
mice, as assessed by IFN-γ production (Figure 7). These
ﬁndings of the experiment using KO mice also support the
conclusionthat TNF-αis a pivotal cytokinethat plays a more
important role than IL-6 in the protection of mice from TB
infection.
It should be noted that in the case of TNFR1 KO
mice, although levels of IFN-γ (Figure 7)a n dI L - 2( d a t a
not shown) in culture supernatant of PPD-stimulated spleen
cells were markedly lower than for control WT mice, IL-6
level was only about 30% lower. This suggests that Th1 cell
function may have been reduced, although IL-6-producing
cell function was relatively well preservedin TNF-α-deﬁcient
mice infected with TB. In addition, even though IL-6
functions normally, TNF is required to protect hosts from
TB infection.
Although anti-IL-6R Ab treatment did not decrease
survival time (Figure 2), IL-6 KO mice died earlier than WT
mice (Figure 6(a)). The following may explain the diﬀerence
in survival results for anti-IL-6R Ab-treated and IL-6 KO
mice. (1) IL-6 KO mice have fewer T lymphocytes and
neutrophils than WT mice [41–43], and this can be expected
toaﬀecthost defenceagainst TBinfection. (2)AllWTDBA/1
mice died within 130 days after challenge with 5 × 105
CFU of TB (Figure 6(a)), whereas BALB/c mice survived
longer under the same conditions (Figure 2), suggesting that
diﬀerences among strains exist in susceptibility to TB. It
is possible that lack of IL-6 aﬀected survival in the more
susceptible strain of mice. (3) It is possible that the dose of
anti-IL-6R Ab injected in this experiment was not suﬃcient
to completely suppress IL-6 function. This seems unlikely,
however, since SAA production was almost completely
suppressed (Table 1)[ 24], and several published papers
support the dose of anti-IL-6R Ab used in this experiment
[44, 45]. (4) Diﬀerences among strains may be involved. In
the antibody-treatment study, BALB/c mice were used, while
in theKOmouse studyDBA/1micewere examined. Stronger
susceptibility of DBA/1 mice to TB infection may have given
rise to the discrepancy in ﬁndings.
Interestingly, anti-TNF-α Ab-treated mice exhibited
increased levels of SAA protein. This ﬁnding contradicts
previously reported results indicating that treatment of
patients with TNF-α blockers decreased serum levels of
acute-phase proteins such as C-reactive protein and SAA [1–
3]. This discrepancy might be explained by increased growth
of TB causing more severe inﬂammation and a resultant
increase in acute-phase reaction.
Regarding whether the murine i.v. infection model we
used fully reﬂects human TB, it should be noted that we have
recently demonstrated that TB vaccination was as eﬀectivein
this murine model as in a cynomolgus monkey intratracheal
infection model [19, 46, 47]. Nevertheless, examination of
the eﬀects of Ab treatments in a model of reactivation of TB
from the latent state may be even more clinically useful.
In summary, the results of these experiments all demon-
strated that anti-IL-6R Ab treatment (and IL-6 KO status)
had much less eﬀect than anti-TNF-α Ab treatment (or
TNFR1 KO status) on the development of TB infection in
mice, suggesting that TNF-α is much more important than8 Clinical and Developmental Immunology
IL-6 in defence against TB infection, and that there may be
less need to limit the clinical use of IL-6 blockers out of fear
of reactivating TB.
KeyMessages
(1)TB-infected mice survived longerwith lessprogression of
infection with IL-6R blockade than with TNF-α blockade.
(2) IL-6R blockade aﬀected immune response to TB in
mice less than TNF-α blockade.
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